3D Systems Corporation reports Q1 2026 results today carrying the most extreme short-side positioning in the ORTEX universe — short interest at nearly 30% of free float, a short score ranked in the bottom percentile. Yet the stock just posted a 31% monthly rally to $2.51. That tension between a crowded short base and a surging price is the defining setup into today's print.
Bears have had a clear grip on this stock. Short interest at 29.6% of free float is exceptionally high. The ORTEX short score of 81.3 — ranked at the 1st percentile for the factor, meaning it scores among the most shorted names in the entire market — reflects how aggressively the short community is positioned. FINRA's official fortnightly count put shares short at 41.3 million, implying more than 14 days to cover. Yet despite that wall of shorts, borrow conditions are not especially punishing. Cost to borrow sits at just 0.54% — almost negligible for a stock this heavily shorted. Availability remains in a moderate range, having eased from earlier peaks this spring. Short interest has also been drifting lower over the past month, down roughly 5.7%, which suggests some shorts have already been covering into the recent price run.
The bull case centres on the company's healthcare pivot. Personalized Healthcare revenue grew 17% year-over-year in the most recent quarter, with FDA-approved parts manufacturing up 18%. Operating expense discipline produced a $5 million year-over-year improvement. Bears point elsewhere: total Q1 revenues fell 8% year-over-year to $94.5 million, missing consensus by a wide margin. Materials sales collapsed 23% on dental aligner inventory issues. The industrial segment — about 56% of revenues — dropped 7% sequentially as customers deferred spending. Analyst coverage is thin and split, with no active buy ratings in the current consensus. Cantor Fitzgerald maintained Overweight in late 2025, raising its target to $4.75, though that action is now more than six months old. Needham has held a steady Hold with no price target through multiple reiterations. The mean analyst target of $3.75, if taken at face value, implies roughly 49% upside from current levels — though the consensus data is stale, from March 2026, and should be viewed cautiously.
Options traders are not showing concern. The put/call ratio at 0.13 is fractionally below its 20-day average and near the 52-week low of 0.12 — call volume is dominating in a way that is unusually one-sided. That call skew aligns with the 30% monthly price recovery and with the notable coordinated insider selling in April, when CEO Jeffrey Graves and multiple EVPs sold shares at $1.87 and $1.98 — well below current levels. The sales were small in dollar terms, but the breadth across the executive team on two separate dates is a notable read. State Street added 1.6 million shares as recently as April 30, the largest recent institutional move in the stock.
Today's print tests whether the healthcare growth story can generate enough momentum to justify a stock that has rallied sharply into one of the most heavily shorted setups in the market.
See the live data behind this article on ORTEX.
Open DDD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
